Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The original Diabetology Axcess formulation (chenodeoxycholate and propyl gallate in a 2:1 ratio wt:wt) has been applied in dogs, using a GLP-1 RA which has been modified to resist not only DPP4 attack, but also breakdown by intestinal proteases ( The work reported by others in dogs, as well as our own results reported here in pigs and rats, show that the Axcess formulation is able to deliver GLP-1 receptor agonists in effective amounts, even at low doses, to the intestinal mucosa
The l-form of this amino acid can be used safely and effectively with many positive benefits
With over 50% of GLP-1 users discontinuing due to cost and 36% due to side effects, Nooms low and slow titration strategy could offer a more sustainable path to weight loss
whether a micro dose meaningfully reduces incidence of a chronic disease in healthy adults is a question the evidence base does not currently answer
Read clinical review
